Market Research Logo

Glomerulonephritis - Pipeline Review, H2 2016

Glomerulonephritis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Glomerulonephritis - Pipeline Review, H2 2016’, provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
    • The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects
    • The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Glomerulonephritis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Glomerulonephritis Overview
    Therapeutics Development
    Pipeline Products for Glomerulonephritis - Overview
    Pipeline Products for Glomerulonephritis - Comparative Analysis
    Glomerulonephritis - Therapeutics under Development by Companies
    Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes
    Glomerulonephritis - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Glomerulonephritis - Products under Development by Companies
    Glomerulonephritis - Products under Investigation by Universities/Institutes
    Glomerulonephritis - Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals, Inc.
    Alexion Pharmaceuticals Inc
    Amyndas Pharmaceuticals LLC
    Anthera Pharmaceuticals Inc
    Avexxin AS
    Biogen Inc
    Complexa, Inc.
    Dimerix Bioscience Pty Ltd
    GlaxoSmithKline Plc
    Mallinckrodt Plc
    Omeros Corporation
    Pfizer Inc.
    Pharmalink AB
    Retrophin Inc.
    Rigel Pharmaceuticals, Inc.
    Shire Plc
    Toray Industries, Inc.
    Variant Pharmaceuticals, Inc.
    Glomerulonephritis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (irbesartan + propagermanium) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ACH-4471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMY-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVX-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    blisibimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    budesonide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    corticotropin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CXA-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fostamatinib disodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    losmapimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-721 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-1355 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-627 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sparsentan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TM-5484 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VAR-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Glomerulonephritis - Dormant Projects
    Glomerulonephritis - Discontinued Products
    Glomerulonephritis - Product Development Milestones
    Featured News & Press Releases
    Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
    May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
    Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
    Mar 04, 2016: Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy
    Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
    Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
    Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
    Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin
    Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin
    Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon
    Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
    Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon
    Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
    Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Glomerulonephritis, H2 2016
    Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Glomerulonephritis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
    Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
    Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
    Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
    Glomerulonephritis - Pipeline by Avexxin AS, H2 2016
    Glomerulonephritis - Pipeline by Biogen Inc, H2 2016
    Glomerulonephritis - Pipeline by Complexa, Inc., H2 2016
    Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
    Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2016
    Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2016
    Glomerulonephritis - Pipeline by Omeros Corporation, H2 2016
    Glomerulonephritis - Pipeline by Pfizer Inc., H2 2016
    Glomerulonephritis - Pipeline by Pharmalink AB, H2 2016
    Glomerulonephritis - Pipeline by Retrophin Inc., H2 2016
    Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
    Glomerulonephritis - Pipeline by Shire Plc, H2 2016
    Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2016
    Glomerulonephritis - Pipeline by Variant Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Glomerulonephritis - Dormant Projects, H2 2016
    Glomerulonephritis - Dormant Projects (Contd..1), H2 2016
    Glomerulonephritis - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Glomerulonephritis, H2 2016
    Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report